ReviewCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2021
Advances in the management of pancreatic ductal adenocarcinoma.
Review in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Case Report: E-cadherin and Vimentin expression in advanced-stage pancreatic ductal adenocarcinoma tissue and circulating tumor cells: preliminary results from a pilot study.Frontiers in oncology · 2026Article
- Hypertension and tachycardia induced by irreversible electroporation in pancreatic cancer: An analysis based on clinical data.World journal of gastrointestinal surgery · 2025Article
- Analysis of an engineered organoid model of pancreatic cancer identifies hypoxia as a contributing factor in determining transcriptional subtypes.Scientific reports · 2025Article
- A severity-based tumor-superior mesenteric/portal vein interface grading criteria as a predictor of survival outcomes in pancreatic head ductal adenocarcinoma patients undergoing pancreaticoduodenectomy following neoadjuvant chemoradiotherapy.Annals of gastroenterological surgery · 2025Article
- The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer.NPJ precision oncology · 2025Article
- The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.Biomolecules · 2025Review
- Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.The oncologist · 2024Article
- Impact of N-Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC).ACS omega · 2024Article
- Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.Molecular cancer · 2023Article
- Determinants of gemcitabine response in pancreatic cancer: are we there?Journal of gastrointestinal oncology · 2023Article
- Inverted Y-shaped technique for complex superior mesenteric / portal vein reconstruction in pancreatoduodenectomy for locally advanced pancreatic head ductal adenocarcinoma.Annals of gastroenterological surgery · 2023Article
- Article
- Pancreatic cancer, radiomics and artificial intelligence.The British journal of radiology · 2022Review
- Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression.The EMBO journal · 2022Article
- Autophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.